Tirzepatide and peptides: what is this dual-receptor medicine?

What exactly is a peptide, and why does it matter for tirzepatide?

A peptide is simply a short chain of amino acids, the same building blocks that make up proteins. When those amino acids are arranged in a specific sequence, the resulting molecule can bind to receptors in the body and produce a biological effect. Tirzepatide is a synthetic peptide engineered to resemble two naturally occurring gut hormones at once: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Neither hormone is new to medicine, but combining activity at both receptors in one injectable molecule is what makes tirzepatide structurally novel.

GIP and GLP-1 are released by the gut after eating. They signal to the pancreas, the brain, and the digestive tract to regulate blood sugar, slow the movement of food through the stomach, and (critically for weight management) reduce appetite. Earlier medicines like semaglutide target the GLP-1 receptor only. Tirzepatide engages both pathways, which researchers believe accounts for its comparatively greater effect on body weight in clinical trials. The full Mounjaro overview covers the licensed indications in more detail.

Because tirzepatide is a peptide rather than a small-molecule drug, it cannot be taken as an ordinary tablet, stomach acid would break the amino-acid chain apart before it could be absorbed. That is why it is given as a once-weekly subcutaneous injection, delivered by a pre-filled pen beneath the skin.

How does the dual GIP and GLP-1 mechanism produce its effects?

GLP-1 receptor activation on its own has measurable effects: it reduces appetite, slows gastric emptying, and prompts insulin release in response to rising blood sugar. GIP receptor activation adds a complementary layer. Research into the tirzepatide peptide structure suggests that GIP activity may amplify the GLP-1-driven appetite reduction and may also influence how fat tissue stores and releases energy, though the full picture is still being investigated.

The practical result, observed across the SURMOUNT clinical programme involving thousands of adults, was that tirzepatide produced average weight reductions considerably larger than those seen with GLP-1-only medicines in similarly designed trials. NICE referenced these findings in its appraisal of tirzepatide, published in December 2024, which recommended the medicine for eligible adults on the NHS in a phased rollout. You can read NICE's full appraisal of tirzepatide (TA1026) for the committee's detailed analysis of the clinical evidence.

It is worth being clear that the mechanism does not make tirzepatide a shortcut. The licensed indication is weight management alongside a reduced-calorie diet and increased physical activity. The peptide supports appetite regulation; the wider lifestyle picture remains part of the treatment.

What does the peptide structure mean for how Mounjaro is used day to day?

Because tirzepatide is a peptide that degrades at higher temperatures, the pen needs to be kept refrigerated (most people find a space in the fridge door works well) at 2–8°C, though there is a limited window during which it can be stored at room temperature for travel or convenience. The exact duration of that window is specified in the Patient Information Leaflet, and you should follow those instructions rather than any general guidance.

Treatment starts at 2.5mg, a dose chosen because it lets the body adjust to the peptide's effects before the dose is increased. The prescriber guides the titration schedule in steps, typically every four weeks, up to the maintenance dose that suits the individual. Tirzepatide carries a Black Triangle (▼) designation, meaning the MHRA is collecting additional safety data, standard practice for newer medicines. The NHS patient information page for tirzepatide is a reliable plain-English reference for day-to-day questions about use and side effects.

For anyone thinking about whether this medicine might be appropriate for them, the clinical picture is always individual. A prescriber reviews health history, current medicines, and BMI before any decision is made. Our guide to GLP-1 and dual-agonist peptides explores the receptor science further if you'd like to go deeper before your consultation.

How does tirzepatide compare to other peptide-based weight-loss medicines available in the UK?

Semaglutide (Wegovy) is the other prescription peptide licensed for weight management in the UK. It is a GLP-1 receptor agonist only (a single-pathway molecule) and its clinical trial results in the STEP programme showed average weight loss of around 15% over 68 weeks at the 2.4mg maintenance dose. In the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks in adults with obesity. That comparison matters, but it is not the only factor in choosing between them, tolerability, medical history, and other medications all play a role that only a prescriber can weigh up.

Other peptide-based medicines exist in diabetes care, and some people encounter references to research peptides or compounded formulations online. These are not the same as licensed Mounjaro. In the UK, the only legal route to tirzepatide for weight management is a prescription following clinical assessment. Our page on peptides and tirzepatide addresses the distinction between licensed medicine and unlicensed compounds directly.

If you would like to understand the dosing schedule in clinical terms, the tirzepatide peptide dosing overview sets out how the titration schedule works and what to expect at each stage. And if you want to explore the cost of private treatment in the UK, our Mounjaro cost guide sets out what private pricing typically reflects and what to look for in a legitimate provider.

When you're ready to find out whether tirzepatide is clinically appropriate for you, our prescribers review every consultation personally. Start your free consultation at our treatment page and a GPhC-registered prescriber will assess your case the same day.